Vancouver, British Columbia — December 18, 2025 — Leads & Copy — BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) has been awarded a $1.6 million grant from the Israeli Innovation Authority (IIA) to advance its Botanical Synthesis™ platform.
The grant, approved under the IIA’s Bio-Convergence program, will support technologies at the intersection of biology, engineering, data science, and artificial intelligence.
The non-dilutive funding will enable BioHarvest to develop new capabilities for its second-generation Botanical Synthesis™ process, advancing its biotechnology innovation while maintaining a strong balance sheet.
The grant will accelerate:
Integration of artificial intelligence-based tools for process optimization, data analytics, and real-time decision-making.
Significant increases in bioreactor size, supporting higher-volume production and improved unit economics.
Expanded autonomous manufacturing functions, enhancing scalability, reproducibility, and operational efficiency.
The Israeli Innovation Authority selected BioHarvest due to its differentiated approach to producing plant-based active compounds through controlled plant cell culture rather than traditional agriculture.
BioHarvest is fully funded to execute its current strategic and operational plans, with approximately $25 million in cash on hand, as a result of prior equity transactions. The IIA grant strengthens the Company’s financial position by supporting advanced R&D without shareholder dilution.
According to Ilan Sobel, CEO of BioHarvest, the grant validates the company’s technology leadership and provides a strategic financial advantage. He stated it allows the company to accelerate the evolution of its Botanical Synthesis™ platform by integrating AI, automation, and larger-scale bioreactors, while preserving capital and maintaining balance sheet strength as it moves toward its second-generation manufacturing capabilities.
The grant was provided by the Israel Innovation Authority in the form of a non-dilutive, zero-interest loan. Repayment is contingent upon the achievement of certain predefined commercial milestones and is expected to be made solely from future revenues generated by the funded project. No equity or equity-linked instruments were issued in connection with the grant.
The Israeli Innovation Authority is a government entity dedicated to fostering Israel’s innovation ecosystem by supporting companies across all stages of technology development, from early research through industrial deployment.
BioHarvest (NASDAQ: BHST) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements.
BioHarvest Corporate Contact:
Dave Ryan, VP Investor Relations
+1 (604) 622-1186
info@bioharvest.com
Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group – MZ North America
+1 (949) 259-4987
BHST@mzgroup.us
Source: BioHarvest Sciences Inc.
